REG - Iconic Labs PLC - Director Appointment

Iconic LabsAnnouncement

20/02/2023 08:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230220:nRST4155Qa&default-theme=true

RNS Number : 4155Q  Iconic Labs PLC  20 February 2023

20 February 2023

 

Iconic Labs PLC

("Iconic" or the "Company")

Director Appointment

 

Iconic Labs PLC (LSE:ICON), is pleased to announce that Emmanuel Blouin has
been appointed to the Board of Directors with immediate effect.

Mr. Blouin has 25 years of investment and banking experience. He was a senior
banker with Morgan Stanley, JP Morgan and BNP Paribas, during which he was
involved in over €50 billion of capital markets, corporate finance and
property transactions across Europe. In 2008, Mr. Blouin established Esterel
Capital, a London-based boutique focusing on real estate and finance, where he
continues to be Managing Partner.

Mr. Blouin is also currently a director of Courbet SA, a hospitality
investment company listed on the Paris Stock Exchange, as well as an
Independent Non-Executive Director of Aradei Capital, a commercial property
investment and management company listed on the Casablanca Stock Exchange.

The following information is disclosed about Mr. Emmanuel Blouin:

 Current Directorships / Partnerships
 Aradei Capital
 Courbet SA
 Esterel Capital LLP
 Stanrock Capital Ltd
 Squareconcept Property Management Ltd

 

Previous Directorships / Partnerships held in the past 5 years: None

Brad Taylor, CEO of Iconic Labs, commented:

"I welcome Emmanuel to the Iconic board of directors. He is a highly skilled
professional with significant expertise in corporate finance and international
dealmaking. This experience, coupled with his vast network, will serve Iconic
and its shareholders well as the company develops and implements an
acquisition and growth strategy. With Iconic directors now in the United
States, United Kingdom, and Europe, we are well-positioned to maximize our
potential for value creation."

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.

- ENDS -

 

For any further information or enquiries please contact:

 

ir@iconiclabs.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOADBLBLXLLZBBK